Marksans Pharma Limited

NSEI:MARKSANS Stok Raporu

Piyasa değeri: ₹132.2b

Marksans Pharma Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Marksans Pharma kazanç ve gelirin sırasıyla yıllık 21.2% ve 16.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 21.3% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 18.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

21.2%

Kazanç büyüme oranı

21.3%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi18.3%
Gelir büyüme oranı16.4%
Gelecekteki özkaynak getirisi18.1%
Analist kapsamı

Low

Son güncelleme05 Sep 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Oct 24
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Jun 21
Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Nov 17
Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Sep 16
This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Sep 01
Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Jun 14
Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

May 27
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Feb 19
Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 04
Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Jan 20
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Jan 05
Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

Dec 21
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

Dec 06
What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely

Nov 19
These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely

Kazanç ve Gelir Büyüme Tahminleri

NSEI:MARKSANS - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
3/31/202735,6905,9744,354N/A2
3/31/202631,1104,8233,460N/A3
3/31/202526,2783,8052,025N/A2
6/30/202422,6803,338N/AN/AN/A
3/31/202421,7743,1372162,304N/A
12/31/202321,0343,164N/AN/AN/A
9/30/202319,9712,9658942,528N/A
6/30/202319,1842,743N/AN/AN/A
3/31/202318,5212,6631,8382,374N/A
12/31/202217,8422,123N/AN/AN/A
9/30/202216,6702,0049721,286N/A
6/30/202215,7561,847N/AN/AN/A
3/31/202214,9081,868529993N/A
12/31/202114,0692,367N/AN/AN/A
9/30/202114,0262,4738831,336N/A
6/30/202114,0642,518N/AN/AN/A
3/31/202113,7622,3851,3221,786N/A
12/31/202013,8172,018N/AN/AN/A
9/30/202013,1421,7241,8392,478N/A
6/30/202012,2031,476N/AN/AN/A
3/31/202011,3441,2081,7342,333N/A
12/31/201910,463879N/AN/AN/A
9/30/20199,97283466416N/A
6/30/201910,099780N/AN/AN/A
3/31/201910,001804142274N/A
12/31/20189,523666N/AN/AN/A
9/30/20189,223582N/AN/AN/A
6/30/20189,272463N/AN/AN/A
3/31/20189,127358N/A501N/A
12/31/20178,918343N/AN/AN/A
9/30/20178,949275N/AN/AN/A
6/30/20178,015187N/AN/AN/A
3/31/20177,672113N/A141N/A
12/31/20167,92670N/AN/AN/A
9/30/20167,948136N/AN/AN/A
6/30/20168,699481N/AN/AN/A
3/31/20168,933785N/A308N/A
12/31/20158,5361,093N/AN/AN/A
9/30/20158,4951,191N/AN/AN/A
6/30/20158,0451,154N/AN/AN/A
3/31/20157,9671,094N/A1,545N/A
12/31/20147,850950N/AN/AN/A
9/30/20147,405897N/AN/AN/A
6/30/20146,914786N/AN/AN/A
3/31/20146,300719N/A648N/A
12/31/20135,9501,020N/AN/AN/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MARKSANS 'nin tahmini kazanç büyümesi (yıllık 21.2% ) tasarruf oranının ( 6.7% ) üzerindedir.

Kazançlar ve Piyasa: MARKSANS şirketinin kazançlarının (yıllık 21.2% ) Indian pazarından (yıllık 18.1% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: MARKSANS şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: MARKSANS şirketinin gelirinin (yıllık 16.4% ) Indian pazarından (yıllık 10.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: MARKSANS şirketinin gelirinin (yıllık 16.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MARKSANS 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 18.1 %).


Büyüyen şirketleri keşfedin